Switzerland · Delayed Price · Currency is CHF Cicor Technologies Earnings Call Transcripts
Fiscal Year 2025
-
Sales rose 28% to CHF 660 million, driven by five acquisitions and strong order intake, with Adjusted EBITDA at CHF 65 million and robust free cash flow. 2026 guidance targets CHF 700–750 million sales and margin improvement as integration progresses.
-
The acquisition creates the largest global pure-play EMS provider in high-mix, low-volume segments, with a strong focus on healthcare, aerospace, and industrial automation. The deal is expected to deliver significant cost synergies, EPS accretion, and enhanced global reach, with closing anticipated in H1 2026.
-
The acquisition will create the largest global pure-play EMS provider in the high-mix, low-volume segment, doubling revenue and delivering significant cost synergies. The deal is highly accretive, with strong stakeholder support, a proven integration approach, and a focus on long-term growth.
-
Record H1 2025 revenue and EBITDA were driven by acquisitions and a return to organic growth in Q2. Raised full-year guidance reflects strong operational momentum, despite FX headwinds and one-time integration costs from Éolane.
Fiscal Year 2024
-
Record 2024 results with revenue up 23% and EBITDA margin improvement, driven by acquisitions and market share gains in core sectors. Guidance for 2025 anticipates CHF 520–560 million in sales, with further growth potential from pending M&A.
-
Strategy 2028 aims for pan-European leadership in electronics design and manufacturing, focusing on high-growth verticals and a CDMO model. Strong organic and M&A-driven growth, operational excellence, and disciplined capital allocation underpin targets of CHF 1 billion revenue and 15% ROIC by 2028.
-
Revenue and EBITDA reached record highs, driven by acquisitions and margin improvements, despite a challenging environment. Guidance for full-year sales and EBITDA was raised, with strong outlooks in aerospace, defense, and medical sectors.